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Ubiquinone-binding site mutagenesis reveals the role
of mitochondrial complex II in cell death initiation
K Kluckova1, M Sticha2, J Cerny1, T Mracek3, L Dong4, Z Drahota3, E Gottlieb5, J Neuzil*,1,4 and J Rohlena*,1
Respiratory complex II (CII, succinate dehydrogenase, SDH) inhibition can induce cell death, but the mechanistic details need
clarification. To elucidate the role of reactive oxygen species (ROS) formation upon the ubiquinone-binding (Qp) site blockade, we
substituted CII subunit C (SDHC) residues lining the Qp site by site-directed mutagenesis. Cell lines carrying these mutations were
characterized on the bases of CII activity and exposed to Qp site inhibitors MitoVES, thenoyltrifluoroacetone (TTFA) and Atpenin
A5. We found that I56F and S68A SDHC variants, which support succinate-mediated respiration and maintain low intracellular
succinate, were less efficiently inhibited by MitoVES than the wild-type (WT) variant. Importantly, associated ROS generation and
cell death induction was also impaired, and cell death in the WT cells was malonate and catalase sensitive. In contrast, the S68A
variant was much more susceptible to TTFA inhibition than the I56F variant or the WT CII, which was again reflected by enhanced
ROS formation and increased malonate- and catalase-sensitive cell death induction. The R72C variant that accumulates
intracellular succinate due to compromised CII activity was resistant to MitoVES and TTFA treatment and did not increase ROS,
even though TTFA efficiently generated ROS at low succinate in mitochondria isolated from R72C cells. Similarly, the high-affinity
Qp site inhibitor Atpenin A5 rapidly increased intracellular succinate in WT cells but did not induce ROS or cell death, unlike
MitoVES and TTFA that upregulated succinate only moderately. These results demonstrate that cell death initiation upon CII
inhibition depends on ROS and that the extent of cell death correlates with the potency of inhibition at the Qp site unless
intracellular succinate is high. In addition, this validates the Qp site of CII as a target for cell death induction with relevance to
cancer therapy.
Cell Death and Disease (2015) 6, e1749; doi:10.1038/cddis.2015.110; published online 7 May 2015
Mitochondrial respiratory complex II (CII), aka succinate
dehydrogenase (SDH), directly links the tricarboxylic acid
(TCA) cycle to the electron transport chain (ETC) bymediating
electron transfer from the TCA cycle metabolite succinate to
ubiquinone (UbQ).1 For this reason, CII is subjected to a high
electron flux between the succinate-binding dicarboxylate site
in the matrix-exposed subunit A and the proximal UbQ-binding
(Qp) site, formed by the subunits C (SDHC) and D embedded
in the mitochondrial inner membrane (Figure 1b).2–5 Disrup-
tion of electron transfer to UbQ, for example by Qp site
inhibition, leads to reactive oxygen species (ROS) generation
from CII due to the leakage of ‘stalled’ electrons to molecular
oxygen at the reduced flavin adenine dinucleotide (FAD)
prosthetic group. However, ROSproduction from reduced FAD
is only possible when the adjacent dicarboxylate site is neither
occupied by its substrate succinate, typically at low succinate
conditions, nor inhibited by other dicarboxylates, for example
by malonate.6–10
Beyond bioenergetics, CII has emerged as an important
factor in cell death induction.11,12 On one hand, it has
been proposed that increased ROS production from CII,
resulting from changes in matrix pH and calcium status,
amplifies cell death signals originating at other sites.12–15 On
the other hand, the inhibition of CII may also directly initiate
cell death, as suggested by our previous results with vitamin
E (VE) analogs such as the mitochondrially targeted VE
succinate (MitoVES). This compound inhibits CII activity
leading to ROS generation and cell death induction in cancer
cells, as evidenced by the suppression of tumor growth in
experimental animal models.16–20 The efficacy of MitoVES is
greatly reduced in the absence of functional CII, and
computer modeling along with other corroborative evidence
suggests that MitoVES binds to the Qp site of CII.
16 However,
this is only circumstantial evidence with respect to cell death
induction, as cells lacking electron flux within CII due to a
structural defect should not be able to produce CII-derived
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ROS. Accordingly, not only the direct cell death initiation upon
CII inhibition will be compromised in this situation, but also
the indirect signal amplification mentioned above will be
affected.
In the present study, we combined site-directed mutagen-
esis of Qp site amino-acid residues with the use of Qp site
inhibitors MitoVES, thenoyltrifluoroacetone (TTFA) and Atpe-
nin A5 to assess the link between Qp site inhibition and cell
death initiation. We show that for MitoVES and TTFA, the
potency of Qp site inhibition correlates with the extent of ROS
production and cell death induction in respiration-competent
CII variants, and that the induced cell death is dependent on
CII-derived ROS.
Atpenin, however, did not induce cell death, possibly due to
the rapid accumulation of succinate in intact cells, incompa-
tible with ROS generation from CII. These results provide
evidence for the role of CII in cell death initiation and establish
the Qp site as a target for cell death induction.
Results
CII Qp site mutagenesis and the experimental model. To
explore the role of CII in cell death induction, we performed
site-directed mutagenesis within SDHC, a CII subunit that
contributes to Qp site formation.
3 We concentrated on SDHC
residues predicted to be in close contact with bound
MitoVES. Serine 68 was mutated to alanine, arginine 72
was replaced by cysteine, and isoleucine 56 was substituted
by phenylalanine (Figure 1). Recent data indicate reduced
cell death induction by MitoVES in the S68A variant,16 but the
functional consequences of this mutation for CII activity have
not been studied. Nevertheless, substitutions of S68 as well
as of R72 are expected to compromise CII activity, based on
analogy with E.coli and S. cerevisiae SDH.21–24 The I56
residue is further away from the Qp site and its role in CII
function is unknown. To evaluate these substitutions, we
utilized a mammalian model of SDHC deficiency, the Chinese
hamster lung fibroblast cell line B9.25 These cells lack the
functional CII due to a nonsense mutation in the SDHC
subunit and fail to assemble CII. In consequence they do not
respire on succinate and are completely devoid of CII
enzymatic activity. Stable transfectants of human wild-type
(WT) and variant SDHC cDNA were prepared in B9 cells, and
the clones with similar level of SDHC were selected. These
cells were further transformed by H-Ras fused to green
fluorescence protein (GFP), making them plausible models to
study the effect of MitoVES and other Qp site inhibitors on
transformed cells (Supplementary Figure S1). Transformants
with similar level of H-Ras were selected to control for
H-Ras level.
Qp site mutations differentially affect CII assembly and
enzymatic function. The selected clones did not signifi-
cantly differ in their mitochondrial content, as evidenced by
similar citrate synthase activity and mitochondrial protein
levels (Figures 2a and b). Mitochondrial morphology and
membrane potential were also similar for all the tested cell
lines (Figures 2c and d). To verify CII assembly, mitochondrial
fractions were subjected to blue native gel electrophoresis
and western blotting using an anti-SDHA antibody. As
expected, parental B9 cells did not assemble CII. In contrast,
CII was fully assembled in WTand most of the SDHC variant
cells (Figure 2e), with a minor assembly defect found
for R72C variant. These results were confirmed using an
in-gel SDH activity assay (Figure 2e), which documented
assembled CII with functional dicarboxylate site in all variants
except for B9 cells. To assess the condition of the Qp site and
its functional coupling to the dicarboxylate site, succinate-
UbQ reductase (SQR) activity in the mitochondrial fraction
was determined. Whereas no SQR activity was measurable
in B9 cells (Figure 2f), it was high in WTand I56F clones. For
S68A and R72C variants the SQR activity was significantly
reduced yet remained above the level of parental B9 cells.
This suggests that although CII assembles properly in all
tested variants, there is a defect in electron transfer to UbQ in
the S68A and R72C variants.
Qp site mutations differentially affect basal CII-driven
respiration under native conditions. As the CII activity
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Figure 1 Amino-acid substitutions in the Qp site of CII. (a) Multiple species
alignment of the SDHC region bordering the Qp site shows a high level of
conservation. Amino-acid substitutions prepared for this study are indicated in human
SDHC. (b) Three dimensional representation of CII and the topology of the Qp site.
SDHC residues mutated in this study are indicated by arrows. Displayed is the
humanized crystal structure of porcine CII.3 (c) A snapshot from molecular dynamics
simulation of MitoVES interaction with the Qp site of CII in the presence of
phospholipid bilayer.16 One of the possible conformations of MitoVES is shown in
orange, substituted SDHC residues are depicted in magenta
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assays described above were done on solubilized enzyme,
we also examined the effect of Qp site mutations on CII-
mediated respiration in a more natural environment of
permeabilized cells. In this set-up respiratory substrates
can reach mitochondria, but the mitochondrial outer and inner
membranes remain intact in their ‘native’, undisturbed
condition.26 In the presence of the CII substrate succinate,
WT, S68A and, in particular, I56F cells efficiently consumed
oxygen. In contrast, R72C and parental B9 cells showed little
or no respiration (Figure 3a). The uncoupler carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone (FCCP) significantly
increased oxygen consumption in WT and I56F, but not in
S68A, R72C or B9 cells (Figure 3a). Hence, the S68A
mutation only affects the reserve capacity of this mutant and
may not be limiting in intact cells. In contrast, a severe defect
in R72C CII substantially compromises its ability to support
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Figure 2 Qp site substitutions do not decrease mitochondrial content, membrane potential or CII assembly, but can compromise CII activity in the presence of detergents.
(a) Citrate synthase was measured in the whole-cell lysates and corrected to the protein content. (b) Selected mitochondrial proteins were analyzed by western blotting using 10 and
20 μg of whole-cell protein. A representative blot is shown along with quantifications based on three independent experiments (c) Mitochondria were visualized by live confocal
microscopy using TMRM, the nuclei were counterstained by Hoechst 33342. Scale bar, 5 μm. (d) Mitochondrial membrane potential was determined as a ratio of TMRM loading
in the presence and absence of FCCP, n= 3, mean± S.E.M. (e) Native blue gel electrophoresis of either digitonin- or lauryl maltoside-solubilized mitochondrial fraction isolated
from CII variant cell lines. Assembled CII was detected by anti-SDHA antibody, or by in-gel SDH activity assay using PMS (phenazine methosulfate). Representative experiments
are shown (f) SQR activity measurement in isolated mitochondrial fraction in the presence of 0.1% Triton X-100 indicates activity impairment for amino-acid substitutions in
position S68 and R72. Data represent mean values± S.E.M. of three independent experiments. The symbol * indicates values significantly different from WT
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respiration. To confirm these findings in intact cells, we
determined the steady-state levels of intracellular succinate,
a proxy for CII activity.27 As shown in Figure 3b, succinate
concentration in WT, I56F and S68A cells was low, consistent
with fully functional CII. On the other hand, in B9 and R72C
cells the succinate levels were considerably increased.
These data demonstrate that whereas B9 and R72C cells
cannot utilize succinate for respiration due to the absent or
dysfunctional CII, WT, I56F and S68A cells maintain CII
respiration under coupled conditions expected to occur in a
physiological situation.
Qp site mutations compromise the efficacy of cell death
induction by MitoVES. Should cell death induction by the
VE analog MitoVES be dependent on its binding to the Qp
site of CII as our previous work suggested,16 then the efficacy
of this agent would be compromised in Qp site mutants.
Hence, the variant cell lines were exposed to MitoVES, a
compound previously described to induce apoptosis,17 and
the percentage of annexin V-positive cells quantified. The
induced cell death displayed signs typical for apoptosis
(Supplementary Figures S2A and B), and was significantly
reduced in all tested variant cell lines compared with WT cells
(Figure 4a). In fact, all substitutions in the Qp site reduced
MitoVES-induced cell death nearly to the level observed in
parental B9 cells. Given the absence of assembled CII in B9
cells, this basal level of cell death must be CII independent
and possibly related to the direct effect of MitoVES on
cytochrome c.28
As ROS generation is the pivotal, early event in the cell
death-initiating cascade induced by MitoVES,16,17 we
assessed ROS production in cultured cells upon MitoVES
treatment with dihydroethidium, a fluorescent probe respon-
sive to superoxide. Compared with WT, all Qp site variant cells
showed reduced ROS formation, which remained at the level
similar to that of parental B9 cells (Figure 4b). In addition,
catalase overexpression and co-treatment with the dicarbox-
ylate site inhibitor malonate reduced cell death and ROS
production in WT cells to the level found in the mutants
(Figures 4c–e). These data indicate that the Qp site mutations
decrease the efficacy of MitoVES-induced ROS generation
and that the induced cell death depends on CII-derived ROS.
Mitochondrial glycerophosphate dehydrogenase (GPD2)
feeds electrons into the mitochondrial UbQ pool similarly to CII
and can also produce ROS. It has recently been shown that
alpha tocopheryl succinate (α-TOS), an untargeted analog of
MitoVES, inhibits GPD2 activity in brown adipose tissue
(BAT).29 However, it is unlikely that GPD2 is responsible for the
observed ROS and cell death induction upon MitoVES
treatment in our experimental model, as the GPD2 levels are
much lower than in BAT (Supplementary Figure S2D). In
addition, GPD2 inhibition by α-TOS decreases, rather than
increases, GPD2-derived ROS29, and MitoVES accumulation
at the inner mitochondrial membrane/matrix interface16 owing
to the mitochondria-targeting triphenyl phosphonium group
will keep it physically separated from the intermembrane
space-localized GPD2. The role of the reverse electron flow
from GPD2 to FAD6 in CII and subsequent ROS generation
from that site can also be discounted, as this would be
inhibited, not stimulated, by MitoVES bound to the Qp site.
Therefore, CII functioning in the forward manner is the likely
source of ROS observed upon MitoVES treatment of the
intact cells.
Sensitivity to Qp site inhibition correlates with the
efficacy of cell death induction unless succinate is
rapidly accumulated. If the attenuated ROS and cell death
induction described above resulted from the reduced
displacement of UbQ by MitoVES at the Qp site of variant
CII, then these variants should display resistance to inhibition
by MitoVES. For this reason, we assessed the effect
of increasing concentrations of MitoVES on CII-driven
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Figure 3 Substitutions in the Qp site affect CII activity less severely in the native environment. (a) Oxygen consumption of digitonin-permeabilized cells respiring on 10 mM
succinate in the presence of rotenone and ADP (coupled) and the maximal rate after addition of FCCP (uncoupled). While I56F and S68A variants support the respiration on
succinate, B9 and R72C cells are deficient. The S68A defect is apparent only upon uncoupling. Mean±S.E.M. of 3–4 independent experiments. The symbol * indicates values
significantly different from WT in the coupled state (oneway ANOVA), the symbol # values significantly different from WT in the uncoupled state (oneway ANOVA) and the symbol
** values significantly increased after FCCP addition (t-test). (b) Intracellular succinate measured by mass spectroscopy in extracts from an equal number of cells indicates
functional CII in the WT, I56F and S68A. Mean± S.E.M. of two independent experiments, the symbol * indicates values significantly different from WT
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respiration at high succinate (10mM). Only respiration-
competent variants, that is WT, I56F and S68A lines, were
used in this experiment. As shown in Figure 5a, the efficacy
of respiration inhibition was reduced for I56F and S68A
variants compared with the WT cells, in direct correlation with
the observed decrease in ROS levels and cell death induction
(see, for example, Figures 4a and b). In contrast to MitoVES,
malonate suppressed oxygen consumption similarly for all
the CII variants tested (Figure 5b), confirming that
the mutations introduced do not substantially affect the
dicarboxylate site.
To better understand this phenomenon, we performed in
silico molecular docking simulation of MitoVES and UbQ with
the Qp site of WT and variant CII. These simulations support
the assumption that steric hindrance and differences in affinity
can explain the less efficient inhibition by MitoVES in S68A
and I56F CII (Supplementary Figures S3B and C). Since
MitoVES is a relatively large molecule (Supplementary Figure
S3A), we also examined the much smaller Qp site inhibitor
TTFA using the same methodology. Surprisingly, the highest
TTFA-binding affinity was calculated for the Qp site of the
S68A variant (Supplementary Figure S3C). We therefore
evaluated oxygen consumption in the presence of increasing
concentrations of this smaller Qp site inhibitor (Figure 5c) and
found that while for the I56F variant the inhibition by TTFAwas
similar to WT cells, the S68A variant was inhibited much more
efficiently. For this reason we speculated that the S68A
mutation could also lead to enhanced cell death induction by
TTFA, which is known to induce apoptosis.14 Indeed, while
ROS and cell death were significantly increased in S68A cells,
only limited ROS and cell death induction were observed in
B9, I56F, R72C andWT cells upon TTFA treatment (Figures 5d
and e). Features typical of apoptotic cell death were observed
(Supplementary Figures S2A and C), and catalase over-
expression or malonate treatment reduced cell death andROS
in S68A cellsmore than inWT cells (Figures 5f–h). These results
suggest a direct correlation between the potency of Qp site
inhibition, CII-mediated ROS production and the extent of
ensuing cell death for MitoVES as well as TTFA.
Surprisingly, the CII Qp site inhibitor Atpenin A5,
24,30 despite
efficient suppression of respiration in WT and I56F cells
(Figure 5i), did not induce cell death or ROS production
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Figure 4 Qp site substitutions lead to reduced cell death induction and ROS generation in response to MitoVES, and the induced cell death is dependent on CII-derived ROS.
(a) Variant cell lines were exposed to 20 μM MitoVES for 24 h and the percentage of annexin V-positive cells was determined by flow cytometry. n≥ 5, mean± S.E.M., * values
significantly different from WT. (b) Variant cell lines were exposed to 2 μM MitoVES for 30 min and the level of ROS was determined by dihydroethidium (DHE) staining and flow
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(e) Cells were exposed to 5 μM MitoVES for 30 min in the presence or absence of 50 mM malonate (30 min pretreatment) and the level of ROS was determined by DHE staining
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(Figures 5j and k). In contrast to MitoVES and TTFA, Atpenin
caused rapid increase of intracellular succinate in intact cells
(Figure 5l), which is incompatible with ROS generation from
CII. Hence, CII inhibition results in cell death only when
succinate accumulation is not too rapid and ROS can
efficiently be produced.
ROS generation in isolated mitochondria correlates with
effective Qp site inhibition at low succinate levels. To
establish the link between ROS production and CII inhibition,
we assessed these two parameters simultaneously in
isolated mitochondria by combining the Amplex Red method
of ROS detection with oxygen consumption measurements.
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We used 0.5 mM succinate, because this concentration
closely reflects its non-pathological intracellular levels (see
Figure 3b) and favors direct ROS production from CII.6,7
Exposure of WT cell mitochondria to increasing concentra-
tions of MitoVES resulted in considerable stimulation of ROS
production. In contrast, ROS generation was limited in S68A
and I56F mitochondria (Figure 6a). A modest level of ROS
production was also observed in R72C mitochondria,
indicating that the low respiration rate of this mutant can still
support ROS generation in response to its inhibition. As
expected, no ROS increase upon MitoVES treatment was
detected in mitochondria from parental B9 cells, which do not
assemble CII (Figure 6b). In addition, the induction of ROS by
MitoVES was malonate sensitive, confirming the involvement
of CII (Figure 6c). Evaluation of oxygen consumption
revealed reduced sensitivity of CII variants to inhibition
compared with WT mitochondria. This effect was visible at
higher concentrations of the inhibitor (Figure 6d), which,
importantly, is within the concentration range where ROS
induction becomes apparent (see Figure 6a). Finally, no
stimulation of ROS production by MitoVES could be detected
at a high succinate concentration (10mM) for any of the
variants tested (Figure 6e), which was confirmed by their
insensitivity to malonate (Figure 6f).
ComparedwithMitoVES,ROS induction by TTFA followed a
different pattern. While for the I56F variant it was similar toWT,
much more ROS were generated by S68A cell mitochondria
(Figure 7a). This is in agreement with the very high sensitivity
of this mutant to the inhibition by TTFA (Figure 5c). Surpris-
ingly, induction of ROS in R72C mitochondria was also
increased, which is supported by computer modeling and is
expected to occur only at low succinate levels not encountered
in intact R72C cells (see Discussion for details; see Figures
3b and 5e, Supplementary Figure S3C). In contrast, no ROS
production was induced in B9 cell mitochondria (Figure 7b).
Similarly to MitoVES, TTFA-induced ROS generation was
suppressed by malonate (Figure 7c), directly implicating CII.
With non-saturating concentrations of succinate, the
build-up of oxaloacetate may lead to CII inhibition at the
dicarboxylate site,6,7,31 complicating the interpretation of
results. Oxaloacetate accumulation is prevented in the
presence of CI inhibitor rotenone, which at the same time
limits reverse electron transfer to CI.8,32 The inclusion of
rotenone in experiments did not substantially alter the
response to either MitoVES (Supplementary Figure S4) or
TTFA (Supplementary Figure S5), excluding these additional
factors. In summary, these results demonstrate that MitoVES
and TTFA induce ROS from CII in direct proportion to their
ability to achieve Qp site inhibition at low, physiological
succinate, which in turn correlates with the efficacy of cell
death induction.
Discussion
In the last decade it has become clear that various complexes
of the mitochondrial ETC have a multifaceted role in the
execution of cell death.33–35 CII has received particular
attention as a target of experimental anticancer agents, and
the inhibition of the Qp site of CII was shown to induce cell
death in cancer cells in vitro and in vivo.16,36,37 Clear evidence
wasmissing, however, because the potential function of CII as
an amplifier of pro-death signals originating elsewhere should
also be considered.13,14 In principle, it cannot be excluded that
a given compound, anticipated to engage the Qp site of CII,
triggers a pro-death signal further upstream, followed by
indirect amplification of this signal at CII. It is impossible to
distinguish between these two scenarios using cellular models
where CII is not assembled or is inhibited at the dicarboxylate
site. Hence, to demonstrate the autonomous role of CII in cell
death induction, functional CII is required.
The CII Qp site variants I56F and S68A employed in this
report respire on succinate similarly to WT under native
conditions, yet display alterations in cell death induction upon
Qp site ligation with MitoVES and TTFA. The level of cell death
induction directly correlates with the efficacy of inhibition of
succinate-driven respiration by these agents. Accordingly,
both I56F and S68A variants were relatively resistant to the
inhibition by MitoVES and to cell death induced by this agent,
whereas the S68A variant, which is more efficiently inhibited
by TTFA, underwent proportionally higher level of cell death
upon TTFA treatment. This likely stems from the altered ability
of the two inhibitors to displace UbQ at the Qp site of the
individual variant proteins. Indeed, experimental data could be
explained by different binding affinities and various degrees of
steric hindrance computationally predicted for variant Qp sites
(Supplementary Figure S3). These observations are consis-
tent with the direct, autonomous role of CII in cell death
Figure 5 Suppression of CII-driven respiration correlates with cell death for Qp site inhibitors that do not rapidly increase the succinate level. (a) Digitonin-permeabilized
respiration-competent variant cell lines respiring on 10 mM succinate in the presence of 0.5 μM rotenone and FCCP were exposed to increasing concentrations of MitoVES. The
variants show reduced inhibition compared with WT. (b) Inhibition by the dicarboxylate-binding site inhibitor malonate in the same experimental set-up shows similar efficiency for
all Qp site substitutions. (c) Similar to a and b, but the Qp site inhibitor TTFA was used. (a–c) The data represent the mean± S.E.M. of 3–4 independent experiments. (d) Variant
cell lines were exposed to 0.5 mM TTFA for 24 h and the percentage of annexin V-positive cells was determined by flow cytometry. n= 5, mean± S.E.M., * values significantly
different from WT. (e) Cells were exposed to 250 μM TTFA for 30 min and the level of ROS was determined by dihydroethidium (DHE) staining and flow cytometry. n= 5,
mean±S.E.M., * values significantly different from WT. (f) Cells were transfected with catalase-coding or control vector, exposed to 2 mM TTFA for 20 h, and the percentage of
annexin V-positive cells was determined by flow cytometry. n= 4, mean±S.E.M., * values significantly different between catalase and mock-transfected cells. Inset, catalase
overexpression verified by western blot. (g) Cells were exposed to 250 μM TTFA for 30 min in the presence or absence of 50 mMmalonate (30 min pretreatment), and the level of
ROS was determined by DHE staining and flow cytometry. n= 4, mean± S.E.M., * values significantly different in the presence and absence of malonate. (h) Cells were
exposed to 1.5 mM TTFA for 12 h in the presence or absence of 20 mM malonate (30 min pretreatment). The percentage of annexin V-positive cells was determined by flow
cytometry. n= 4, mean± S.E.M., * values significantly different in the presence and absence of malonate. (i) Atpenin A5-induced inhibition of respiration of permeabilized cells as
described in a. n≥ 3, mean± S.E.M. (j) Cells were exposed to 1 μM Atpenin A5 for 24 h and the percentage of annexin V-positive cells was determined by flow cytometry. n= 3,
mean±S.E.M. (k) Cells were exposed to 0.5 μM Atpenin A5 for 30 min and the level of ROS was determined by DHE staining and flow cytometry. n= 5, mean±S.E.M.
(l) Succinate levels were determined in WT cells exposed to 20 μM MitoVES, 1 mM TTFA or 1 μM Atpenin A5 for 30 min. n= 3, mean± S.E.M., * values significantly different
from control
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initiation by these agents, and cannot be reconciled with the
role of CII as amere amplifier of upstream effects originating at
other sites. The engagement of cell death induction pathways
unrelated to CII can be also discounted. In the latter scenarios,
all variants retaining CII activity would behave similarly, which
is clearly not the case.ComparedwithWT cells, the variant cell
lines show lower response to MitoVES but higher (or similar)
level of cell death upon TTFA treatment. This indicates that the
mutations are not associated with nonspecific defects in cell
death induction in our system, and excludes CII-unrelated
ROS sources such as GPD2. Accordingly, this study
establishes, for the first time, a direct connection between
CII inhibition at the Qp site and initiation of cell death.
In sub-mitochondrial particles, it has been previously
established that CII can produce ROS upon Qp site inhibition
only when FAD is reduced and the dicarboxylate site is
unoccupied.7,38 In intact cells, this introduces an additional
level of complexity, because the lack of enzymatically active
CII will result in the accumulation of its substrate succinate due
to the poor membrane permeability of this metabolite.27
Succinate then might block the dicarboxylate site and restrict
oxygen access to FAD, attenuating ROS production.6 Indeed,
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Figure 6 ROS induction by MitoVES correlates with CII inhibition in isolated mitochondria at low succinate. (a and b) Mitochondria isolated from variant cells respiring on
500 μM succinate in an oxygraph chamber were exposed to increasing concentrations of MitoVES, and ROS production was followed in real time in the presence of Amplex Ultra
Red and peroxidase. (a) Shows reduced ROS production for I56F and S68A variants compared with WT, (b) shows the same for R72C and B9 cells. The same WT data are used
in a, b, the panels are separated for clarity only. (c) Under the same conditions, 5 mM malonate inhibits ROS generation by 70 μM MitoVES in all cell lines except for B9 cells.
(d) Respiratory data extracted from the experiments shown in a reveal that the respiration of WT cells is inhibited by MitoVES most efficiently. (e) ROS were measured as in a, b,
but at 10 mM succinate. No increase in ROS generation was detected. (f) At 10 mM succinate there is no effect of 5 mM malonate on ROS at 70 μM MitoVES. Data represent
the mean± S.E.M. of 3–5 independent experiments. Significant differences from WT: *I56F, **S68A, #B9, ##R72C. Panel c: * denotes a significant decrease after the addition of
malonate
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the R72C mutation associated with low residual enzymatic
activity of CII did not reduce the TTFA-dependent induction of
ROS in isolated mitochondria where succinate is low
(Figure 7b, Supplementary Figure S5B), but suppressed
TTFA-induced ROS and cell death in intact cells where
succinate is high (Figure 3b, Figures 5d and e). Similarly,
Atpenin A5, a high-affinity Qp site inhibitor,
24,30 did not induce
ROS and cell death in intact cells (Figures 5j and k) in this and
an unrelated39 study, even though it had been previously
shown to efficiently generate ROS from CII in sub-mito-
chondrial particles, where succinate cannot accumulate.7
We propose that in intact cells the blockade of the dicarbox-
ylate site of Atpenin-inhibited CII, possibly by oxaloacetate as
reported6 or by the rapidly accumulated succinate (Figure 5l),
is the likely reason for this discrepancy. This is consistent with
the known behavior of CII and suggests that CII is the bona
fide source of ROS in intact cells upon Qp site inhibition.
Furthermore, co-treatment with dicarboxylate site inhibitor
malonate suppressed ROS generation and cell death upon
MitoVES and TTFA administration in responsive cell lines, and
MitoVES/TTFA-induced cell death was catalase sensitive
(Figures 4c–e, Figures 5f–h). We therefore propose that cell
death will be induced only when the Qp site is inhibited
in a manner that allows ROS to be generated (Figure 8).
Accordingly, Qp site inhibition that is too efficient or rapid, such
as with Atpenin, will suppress all CII activity and reduce FAD,
but at the same time block the dicarboxylate site by succinate
(or other dicarboxylate), quenching ROS formation. Slower,
less efficient inhibition, such as with MitoVES or TTFA,
will leave some CII molecules unoccupied, slowing down
succinate accumulation such that the Qp site-blocked CII
molecules can produce ROS and induce cell death. Reduction
of Qp site inhibition by mutations that do not reduce CII activity
will then leave insufficient number of Qp site-blocked CII
molecules to generate ROS, whereas mutations that compro-
mise CII activity will upregulate succinate, limiting the ROS
production from FAD.
In conclusion, the data presented in this study provide
support for the direct role of CII in cell death initiation by
demonstrating a clear correlation between the efficacy of
inhibition at the Qp site of CII and themagnitude of cell death in
respiration-proficient CII variants for Qp site inhibitors that do
not excessively upregulate succinate. Despite being focused
on CII, our results may also be relevant for other ETC
complexes, as many ETC inhibitors reported to promote cell
death also modulate cell death pathways independent of the
ETC. For example, the CI inhibitor rotenone destabilizes
microtubules,40,41 and the CII inhibitor α-TOS as well as the
complex III inhibitor antimycin act as BH3mimetics.42,43 To our
knowledge, it has never been unequivocally shown for any of
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Figure 7 ROS induction by TTFA also correlates with CII inhibition in isolated mitochondria at low succinate levels. (a and b) Mitochondria isolated from variant cells respiring
on 500 μM succinate in an oxygraph chamber were exposed to increasing concentrations of TTFA, and ROS production was followed in real time in the presence of Amplex Ultra
Red and peroxidase. (a) Shows increased ROS production for S68A variant compared with WT, (b) shows the higher ROS for R72C and no ROS for B9 cells. The same WT data
are used in a and b, the panels are separated for clarity only. (c) Under the same conditions, 5 mMmalonate inhibits ROS generation by 825 μM TTFA in all cell lines except for B9
cells. (d) Respiratory data extracted from the experiments shown in a reveal that the respiration of S68A cells is inhibited by TTFA most efficiently. Data represent mean±S.E.M.
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these compounds that ETC inhibition is instrumental in cell
death induction by correlating ETC inhibitory efficacy of a
single compound at any of the ETC complexes with the extent
of cell death. Hence, this report defines the Qp site of CII as a
suitable target for cytotoxic agents and demonstrates that ETC
targeting may present a potential clinically relevant approach
to cancer treatment.44
Materials and Methods
Chemicals and reagents. All chemicals and reagents were from Sigma
(St. Louis, MO, USA), unless otherwise stated. MitoVES was synthesized in-house
as described earlier.16 Atpenin A5 was from Enzo Life Sciences (Farmingdale, NY,
USA).
Cell culture. Parental cells and variant cell lines were cultured in high-glucose
(4.5 g/l) DMEM medium (Lonza, Basel, Switzerland) supplemented with 10% FCS,
non-essential amino acids (both Life Technologies, Carlsbad, CA, USA) and
antibiotics at 37 °C and 5% CO2. Eahy926 cells were cultured as described in
Rohlena et al.18
Qp site mutagenesis and the generation of variant cell lines.
Generation of the S68A variant was described earlier.16 For other variants, site-
directed mutagenesis of human wt SDHC cDNA was performed in the pEF-IRES-
PURO expression vector using the QuickChange Lightening mutagenesis kit
(Stratagene, La Jolla, CA, USA) and the following mutagenesis primers: I56F, 5′-gtc
ctctgtctccccactttactatctacagttgg-3′ (forward), 5′-ccaactgtagatagtaaagtggggagac
agaggac-3′ (reverse), R72C, 5′-gatgtccatctgccactgtggcactggtattgc-3′ (forward),
5′-gcaataccagtgccacagtggcagatggacatc-3′ (reverse). The sequences were confirmed
by DNA sequencing and used to transfect the SDHC-deficient B9 fibroblasts using the
Attractene reagent (Qiagen, Hilden, Germany), followed by incubation with 2–4 μg/ml
puromycin for 2 weeks. Clones were analyzed for the expression of human SDHC by
RT-PCR and those selected were stably transfected with pEGFP-C3-H-Ras as
described with the exception of using Attractene for transfections,36 after which
transfectants with similar level of GFP-H-Ras expression were selected. Total RNA was
collected, and the presence of the variant transcript was verified by cDNA sequencing.
Quantitative Real time-PCR. Was performed essentially as described.16
Primers for human SDHC detection were 5′-cacttccgtccagaccggaac-3′ (forward)
and 5′-atgctgggagcctcctttcttca-3′ (reverse).
Western blotting. Cells were lysed in RIPA buffer (150 mM NaCl, 1.0%
Nonidet NP-40, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0)
supplemented with protease and phosphatase inhbibitors for 30 min with shaking on
ice. Protein content was determined by the BCA assay (Pierce, Rockford, IL, USA).
Samples were boiled for 5 min in reducing loading buffer before separation on SDS-
PAGE gels. Wet blotting was used to transfer the separated samples to
nitrocellulose membranes (Whatman-GE, Little Chalfont, UK). Immunoblotting
was done in TBS/tween supplemented with 5% non-fat dried milk overnight at 4 ºC.
Following antibodies were used: anti-H-Ras (Santa Cruz, Dallas, TX, USA, sc-520),
anti-actin HRP labeled (Cell Signaling, Danvers, MA, USA, 5125), unlabeled actin
(Millipore, Darmstadt, Germany, MAB1501, used for Figure 2b), anti-cleaved
caspase 3 (Cell Signaling, 9664), anti-catalase (Abcam, Cambridge, UK, Ab1877),
Anti-Vdac1/porin (Abcam, ab15895), anti-SDHA (Abcam, ab14715), anti-ATPase
alpha subunit (Abcam, ab14748). Rabbit polyclonal antibody to GPD2 was custom
prepared.45 HRP-conjugated secondary antibodies were used in TBS/tween with
5% non-fat dried milk for 1 h at room temperature. WB signals were quantified using
the Aida 3.21 Image Analyzer software (Raytest, Straubenhardt, Germany).
Mitochondria isolation. Mitochondrial isolation was performed according to
a recently described method, with some adaptations.46 Cells were released by
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Figure 8 A proposed model of cell death initiation at CII explaining the regulation of ROS production from reduced FAD group in intact cells. (a) High-affinity Qp site inhibitors, such as
Atpenin A5, will immediately block most of the available Qp sites in a cell and rapidly upregulate intracellular succinate. CII will be inhibited and FAD reduced, but no ROS will
be produced, because succinate in the dicarboxylate site will block oxygen access. (b) Medium affinity inhibition such as with MitoVES or TTFA will not immediately block all
the available Qp sites, and some free CII will be left to keep succinate levels from rising rapidly. Because of the free dicarboxylate site, the reduced FAD in Qp-inhibited CII
molecules will be able to produce cell death-inducing ROS. (c) Mutations in the Qp site that do not affect CII activity will lower the ability of an inhibitor such as MitoVES to
displace ubiquinone, and despite low intracellular succinate FAD will not be reduced and therefore unable to produce ROS. (d) Qp site mutations that affect CII activity will
upregulate succinate, blocking dicarboxylate site and preventing ROS generation from FAD. Additional Qp site inhibition will not generate ROS under these conditions
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trypsin, washed in PBS, and 40–50 × 106 cells were transferred to 5 ml of
mitochondria isolation buffer (200 mM sucrose, 1 mM EGTA, 10 mM Tris/Mops pH
7.4). The cell suspension was homogenized by three passes through a cell
homogenizer (Isobiotec, Heidelberg, Germany) set to 10 μm clearance using 5 ml
syringe (SGE, 5MDF-LL-GT) at 0.5 ml/min flow at 4 ºC. The homogenate was
centrifuged (at 4 ºC) at 800 × g for 8 min, the supernatant was collected and pre-
cleared at 3000 × g for 5 min. The final collection of mitochondrial pellet was done at
10 000 × g for 15 min. Protein content was determined by the BCA assay. The
mitochondria were undamaged, viable and well coupled, as determined by
respirometry (see below) from their reaction to the addition of ADP (about 5x
increase in respiration), FCCP (substantial increase of respiration) and cytochrome
c (no or very little increase in respiration).
Blue native electrophoresis. Isolated mitochondria were solubilized in the
extraction buffer (1.5 M aminocaproic acid, 50 mM Bis-Tris, 0.5M EDTA and pH 7)
containing 1.3% lauryl maltoside or 8 g digitonin / g protein. Samples comprising
20–30 μg of protein were then mixed with the sample buffer (0.75 M aminocaproic
acid, 50 mM Bis-Tris, 0.5M EDTA, pH 7, 5% Serva-Blue G-250 and 12% glycerol)
and loaded on the precast NativePAGE Novex 4–16% Bis-Tris gels (Life
Technologies) and run overnight at a constant voltage of 25 V. Separated protein
complexes were then transferred to the PVDF membrane (Millipore), using the
Trans-Blot Turbo transfer system (Biorad, Hercules, CA, USA). CII was detected
with the anti-SDHA (2E3) antibody (Abcam, AB14715-200).
In-gel SDH activity. Lauryl maltoside (20–30 μg) or digitonine solubilized
mitochondria (see above) were mixed with sample buffer containing 50% glycerol
with 0.1% Ponceau dye and run on the precast NativePAGE Novex 4–16% Bis-Tris
gel at constant voltage of 100 V, which was raised to 500 V after the samples
entered the separation gel. Deoxycholate (0.05% ) and lauryl maltoside (0.01%)
were added to the cathode buffer for higher resolution as described.47 Gels with
separated protein complexes were incubated for 30 min in assay buffer containing
20 mM sodium succinate, 0.2 mM phenazine methosulfate and 0.25% nitrotetra-
zolium blue in 5 mM Tris/HCl, pH 7.4. The reaction was stopped using solution of
50% methanol and 10% acetic acid and gels were immediately photographed.
SQR activity measurement. Mitochondria (25 μg) were incubated in 200 μl
of 25 mM phosphate potassium buffer (pH 7.4) containing 0.1% Triton X-100, 20 mM
succinate, 2 μM antimycine, 5 μM rotenone, 10 mM sodium azide, 50 μM
decylubiquinone for 3–5 min in a 96-well plate. After 30 s recording of the
measurement at 600 nm, 10 μl of 2,6-dichlorphenol indophenol (0.015% w/v) was
added and the reaction was recorded for another 2–3 min. Identical measurements
were performed in the presence of 20 mM malonate and the net SQR activity was
obtained by subtracting malonate-insensitive rates.
Mitochondrial membrane potential measurements. Cells were
seeded in 12-well plates a day before the experiment. On the day of experiment,
one well was used to determine the total cellular protein by BCA. The rest of the
cells were collected by trypsin, washed with PBS, and resuspended in Mir05
medium (see below) at 0.5 mg/ml concentration with 10 mM succinate, 2 mM
malate, 10 mM glutamate, 3 mM ADP and 20 nM tetramethylrhodamine methyl ester
(TMRM). Next, 60 μl of this cell suspension was permeabilized with 0.1 μg digitonin
per μg protein for 5 min at room temperature, and immediately measured on
LSR-II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) for the
TMRM fluorescence signal. Finally, 0.2 μl of 1 mM carbonyl cyanide
3-chlorophenylhydrazone (CCCP) was added and the TMRM signal after
uncoupling was assessed. The relative mitochondrial membrane potential was
determined as the ratio of TMRM signal before and after the addition of CCCP (f/f0).
Confocal microscopy. Live confocal images were obtained basically as
described48 with minor modifications. The cells in complete medium in microscopy
glass-bottom dishes were incubated with 250 ng/ml Hoechst 33342 nuclear stain
and 10 nM TMRM for 15 min and imaged with x63 oil immersion lens at the heated
stage of an SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany).
2-μm-thick stacks were obtained, deconvoluted with the Huygens Professional
software (SVI, Hilversum, The Netherlands) and presented as maximal intensity
projections.
Determination of intracellular succinate. Cells were cultured for 24 h,
washed with PBS, scrapped and extracted in 96% ethanol in a cold methanol bath.
Extracts corresponding to equal number of cells were used in further analysis (106
cells per 1.6 ml). After the addition of the internal standard the extracts were dried
under argon stream. Afterwards, 50 μl of benzyl alcohol and 30 μl of TMS-chloride
were added to the dried samples, and the closed Eppendorf tubes were placed in
the ultrasonic bath (room temperature, 45 min) and in an oven (80 °C, 45 min).
A final volume of 500 μl was adjusted by adding acetonitrile. Quantification of the
derivatized acids was performed with an LC–ESI/MS system (Bruker Esquire 3000,
Billerica, MA, USA), in positive ionization mode. The mass spectrometer was
connected to a liquid chromatography system of the 1100/1200 series from Agilent
Technologies (Santa Clara, CA, USA). Reversed-phase separation of the derivatives
was performed on a Supelcosil 150 × 4.6 mm column with a silica-based C-18
stationary phase (5-μm particle diameter). The mobile Phase A was acetonitrile and
Phase B was H2O, 0.1% formic acid. Agilent ChemStation for LC 3D systems
B01.03 was used to control the instruments and for data processing. The gradient
program was 0 min 50% B, from 0 to 8 min to 5% B and at 20 min back to the initial
conditions of 50% B. The injection volume was 10 μl. The LC separation and the
ESI settings of the Esquire instrument were optimized utilizing a dibenzyl oxalate as
an internal standard. Intracellular succinate concentration was calculated using an
average cell diameter of 14 μm.
Measurement of CII respiration in permeabilized cells. Cells were
collected by trypsinization, washed in PBS, resuspended in Mir05 medium (0.5 mM
EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4,
110 mM sucrose, 1 g/l essentially fatty acid-free BSA, 20 mM Hepes, pH 7.1 at
30 ºC) and transferred to the chamber of the Oroboros Oxygraph-2k (Oroboros
Instruments, Innsbruck, Austria) for respiration measurements at 37 ºC. The
chamber was closed when the oxygen signal became stable, and after recording the
routine respiration on intracellular substrates the plasma membrane was
permeabilized by 10 μg digitonin per million cells. The CII respiration was
determined in the presence of 0.5 μM rotenone, 10 mM succinate, 3 mM ADP and
10 μM cytochrome c. The maximal respiration in the uncoupled state was then
achieved by FCCP titration in 0.5 μM steps. Antimycin A (2.5 μM ) was added at the
end to inhibit ETC and the residual oxygen consumption after antimycin addition
was subtracted from all the results to obtain the mitochondria-specific rates.
Inhibition of CII respiration. Cells were permeabilized as above and the
effect of CII inhibitors was assessed in the presence of 10 mM succinate, 3 mM
ADP, 0.5 μM rotenone, 10 μM cytochrome c and FCCP. The inhibitors (MitoVES,
TTFA, Atpenin A5 or malonate) were titrated to the chamber in regular intervals
(5 min) and the rate of oxygen consumption was assessed after each addition.49
Solvent only was titrated into control chambers in parallel to check for nonspecific
effects and cell deterioration, but the respiration rates remained virtually unaffected
(o10% decrease at the end of the experiment). Respiration rates after 2.5 μM
antimycin A addition were subtracted to obtain the mitochondria-specific rates.
Simultaneous measurements of ROS production and oxygen
consumption in isolated mitochondria. The chambers of the Oroboros
Oxygraph instrument equipped with the O2k-Fluorescence LED2-Module (Oroboros
Instruments) were calibrated at 37 °C with the Budapest-modified respiration
medium ( 120 mM KCl, 20 mM HEPES, 10 mM KH2PO4, 2.86 mM MgCl2, 0.2 mM
EGTA, 0.025% BSA, pH 7). After closing the chambers, Amplex Ultra Red
(Life Technologies) and peroxidase were injected (at final concentrations 5 μM and
1 U/ml, respectively), followed by the addition of 200 μg of isolated mitochondria,
0.5 μM rotenone (where indicated), 0.5 or 10 mM succinate and 3 mM ADP. The
tested inhibitors were titrated as above, and the amount of hydrogen peroxide
generated was determined based on the conversion of Amplex Ultra Red to the
highly fluorescent product resorufin50 using excitation LED 525 nm equipped with
the Amplex red filter set. Oxygen consumption was recorded simultaneously in the
same chamber. Malonate (5 mM) was added at the end of the titration experiment to
confirm that the signal is succinate dependent. After this, hydrogen peroxide of
known concentration was titrated to the chamber in several steps to calibrate the
fluorescence signal. Finally, 2.5 μM antimycin A was added to subtract the
nonspecific respiration rates.
ROS measurement in intact cells. The cells were seeded in 12-well
culture plates and grown for 24 h. To start the experiment, tested compounds were
added to the culture medium and after 15 min, dihydroethidium was added to the
final concentration of 20 μM. After another 15 min, the cells were harvested by
trypsin and oxidized ethidium fluorescence was measured on a LSR-II flow
cytometer (Becton Dickinson) and expressed as a mean fluorescence intensity.
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Cell death measurements. Cells were seeded in 12-well culture plates and
grown for 24 h. After that, the tested compounds were added as indicated. The
medium was collected after the required incubation time, the adherent cells were
washed by PBS and harvested by trypsin. All these fractions were combined,
washed by PBS and incubated with PE- or Dy647-labeled annexin V (Becton
Dickinson and Apronex, Vestec, Czech Republic) in the supplied binding buffer for at
least 10 min. Hoechst 33258 was added to mark the cells with ruptured cell
membrane. Annexin V-positive fraction was measured by flow cytometry. The results
were expressed as the percentage of annexin V-positive cells. For the catalase
experiments, cells were transfected two days before the experiment with a control or
catalase-containing vector (a kind gift of Dr. S Lortz)51 using the Fugene transfection
reagent (Promega, Fitchburg, WI, USA) according to manufacturer’s instruction.
Computer modeling. The structure of WT human mitochondrial complex II was
obtained as a homology model based on the highly homologous template of the
porcine CII3 (pdb id 1zoy, sequence identity 95, 96, 92, and 88% for SDHA to SDHD)
using the Modeller suite of programs.52 The single point SDHC mutations (I56F, S68A,
R72C) were then introduced using the FoldX program,53 which was also used to
optimize the side chain rotamers within the WT as well as mutated structures. All the
structures were further subjected to a short (10 ns, implicit solvation) molecular
dynamics (MDs) run in order to relax the potentially non-equilibrium structures. The
MD was prepared and performed using the GPU version of the GROMACS suite
of programs54 as implemented in the OpenMM Zephyr package.55 Average
structures from second half of the simulations were further used for the docking
study. The docking study of the MitoVES, TTFA and ubiquinone ligands/inhibitors
to a series of mutated mitochondrial complex II structures was performed using
the autodock suite of programs.56 The ligands were docked into the homology
model of human CII and its single point mutants using Python Molecular Viewer
version 1.5.6rc3.57 Each ligand was allowed to sample docking poses in a box
(70 × 70 × 70 grid points with 0.375 Å spacing) centered at the level of the
ubiquinone binding site (based on the crystal structure). The side chains of
residues surrounding the binding site were considered flexible. A series of four
separate “local search” runs of 50 cycles each was performed and the results
were combined to find the most stable poses.
Statistical analysis. Statistical analysis was performed using GraphPad Prism
6 software (GraphPad Software, La Jolla, CA, USA). Statistical significance was
determined by oneway ANOVA followed by Dunnett’s post test. For pair-wise
comparisons (Figures 3a and 4c–e, Figures 5f–h, Figures 6c and 7c,Supplementary
Figures S4C and S5C), we used unpaired t-test. P≤ 0.05 was considered statistically
significant. The value of n indicates the number of independent experiments.
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